*These adverse reactions were common (≥ 1/ 100 to < 1/ 10) in CHB patients treated with Pegasys monotherapy
* Neid kõrvaltoimeid esines sageli (≥1/ 100 kuni < 1/ 10) Pegasys- monoteraapiat saanud kroonilise B- hepatiidiga patsientidel